Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CryoLife, Inc.
While global vaccine heavyweights Merck & Co, Sanofi and GSK are so far not faring so well to successfully develop a vaccine for COVID-19, smaller players are stepping up. That's especially true for segmented markets such as China.
The Ascyrus Medical Dissection Stent is designed to help remodel the aortic arch following an aortic dissection. CryoLife will pay up to $200m for Ascyrus.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Private Company Edition: VC deals are surging this year for cell and gene therapy firms, according to ARM’s third quarter report. Also, Vivo Capital and the CF Foundation plan to invest nearly $2bn in health care and life science opportunities, and Akeso completes $150m series D.
- Implantable Devices
- Other Names / Subsidiaries
- Cardiogenesis Corporation
- CryoLife Asia Pacific, Pte. Ltd.
- CryoLife Europa Ltd
- CryoLife France, SAS
- JOTEC AG
- JOTEC Cardiovascular SL.
- JOTEC Polska Sp. z o.o.
- JOTEC s.r.l.
- On-X Life Technologies Holdings, Inc.
- Ascyrus Medical LLC